Journal
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
Volume 103, Issue 11, Pages 3474-3482Publisher
WILEY
DOI: 10.1002/jbm.a.35489
Keywords
methylprednisolone; chitosan; spinal cord injury; gene delivery
Funding
- Korean Health Technology RD Project
- Ministry of Health Welfare
- Republic of Korea [A120254-1201-0000300]
- National Research Foundation of Korea from the Korean Government [2012-0001560]
Ask authors/readers for more resources
Methylprednisolone (MP) is a glucocorticoid that is used as an anti-inflammatory agent to the treat spinal cord injury (SCI). A low molecular weight chitosan was used to synthesize chitosan-MP conjugate, which was used to evaluate the gene therapy, anti-inflammatory and anti-apoptotic effects of MP. The cytotoxicity of chitosan-MP nanoparticles and the transfection efficiency of plasmid DNA were evaluated by MTT and luciferase assays. A chitosan-MP/pDNA complexes was injected into injured spinal cord to evaluate the anti-inflammatory and anti-apoptotic effects of these complexes using terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) and ED1 staining, respectively. In addition, to evaluate the distribution of chitosan-MP/pDNA complexes, p-gal encapsulated chitosan-MP was injected into the injected site. Cell survival was similar in cells treated with chitosan-MP conjugate and untreated cells. Luciferase expression was higher in cells treated with the chitosan-MP/pDNA than cells treated with the chitosan/pDNA. The chitosan-MP/pDNA complexes also reduced apoptosis and inflammation at the injury site. These results suggest that chitosan-MP conjugation is an effective gene delivery system to treat SCI. (c) 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 103A: 3474-3482, 2015.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available